Gómez J M, Virgili N, Soler J, Fernández M, Montaña E
Servicio de Endocrinologia, Hospital de Bellvitge, Barcelona, España.
Thyroidology. 1989 Dec;1(3):149-52.
One hundred twenty six patients with Graves' disease, 26 with toxic multinodular goiter, and 18 with toxic adenoma were treated with 131I (3-15 mCi), and followed at monthly intervals for six months. Transient hypothyroidism occurred at two months in 22 patients with Graves' disease. In this state TSH levels became elevated in seven patients, but were normal or suppressed in seven. In 17 patients T4 and T3 levels returned to normal without T4 replacement. Five patients developed recurrent thyrotoxicosis, and required repeated doses of 131I. The possibility of transient hypothyroidism in the early months after 131I therapy in Graves' disease should be borne in mind.
126例格雷夫斯病患者、26例毒性多结节性甲状腺肿患者和18例毒性腺瘤患者接受了131I(3 - 15毫居里)治疗,并每月随访6个月。22例格雷夫斯病患者在两个月时出现短暂性甲状腺功能减退。在此状态下,7例患者促甲状腺激素(TSH)水平升高,但7例患者的TSH水平正常或受到抑制。17例患者的T4和T3水平在未进行T4替代治疗的情况下恢复正常。5例患者出现复发性甲状腺毒症,需要重复给予131I治疗。应牢记格雷夫斯病患者在131I治疗后的最初几个月出现短暂性甲状腺功能减退的可能性。